Announced Sat, 18 Jul · 09:32 IST
USFDA inspection at Cipla's InvaGen facility ends with 1 observation
Regulatory & Legal View source PDF
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.0%1-day move
₹1419.30
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+1.0-0.2-1.7-0.7-0.3—————
Up moveDown movePending
AI summary
InvaGen, Cipla's wholly owned US subsidiary, underwent a routine USFDA cGMP inspection at its Central Islip, New York facility from 13-17 July 2026. The inspection ended with 1 Form 483 observation. Cipla plans to address it within the stipulated time.
Likely market impact
A single observation is largely routine with limited near-term impact. Watch for escalation if it turns into a warning letter.